Premium
Long‐term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome
Author(s) -
Kizaki Masahiro,
Miyakawa Yoshitaka,
Ikeda Yasuo
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04504.x
Subject(s) - megakaryocyte , medicine , myelodysplastic syndromes , adverse effect , recombinant dna , thrombopoietin , immunology , stem cell , oncology , haematopoiesis , bone marrow , biology , biochemistry , genetics , gene
Summary. To date, there are no curative therapeutic options for patients with myelodysplastic syndromes (MDS) other than allogeneic stem cell transplantation. We treated an MDS patient with 10 µg/kg pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF) for more than 450 d. The patient's platelet counts increased from < 10 × 10 9 /l to 50 × 10 9 /l. Interestingly, haemoglobin levels increased dramatically and reached over 13 g/dl without additional transfusion. Adverse events and neutralizing antibodies were not observed during treatment, suggesting that the long‐term administration of rHuMGDF might be of clinical benefit to patients with MDS.